The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Early clinical experience with the pan-FGFR inhibitor rogaratinib in patients with non-small cell lung cancer selected based on FGFR mRNA expression levels.
 
Markus Joerger
No Relationships to Disclose
 
Byoung Chul Cho
Stock and Other Ownership Interests - Theravance
Honoraria - AstraZeneca; Bayer; Champions Oncology; Dizal Pharma; Dong-A ST; Janssen; Mogam Biotechnology Research Institue; MSD; Novartis; Ono Pharmaceutical; Yuhan
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche; Takeda; Yuhan
Speakers' Bureau - Novartis
Research Funding - AstraZeneca; Bayer; Champions Oncology; Dizal Pharma; Dong-A ST; Janssen; Mogam Biotechnology Research Institue; MSD; Novartis; Ono Pharmaceutical; Yuhan
Patents, Royalties, Other Intellectual Property - Champions Oncology
 
Nicolas Mach
Stock and Other Ownership Interests - Novartis
 
Cristina Caballero
No Relationships to Disclose
 
Ross A. Soo
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche/Genentech; Taiho Pharmaceutical; Takeda; Yuhan
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Celgene; Merck Sharp & Dohme; Novartis; Pfizer; Roche/Genentech; Taiho Pharmaceutical; Takeda; Yuhan
Research Funding - AstraZeneca
 
Manfred Wirth
Honoraria - Amgen; Apogepha; Astellas Pharma; Bayer/Vital; Janssen-Cilag; Merck; MSD; Novartis; Orion; Solution Akademie GmbH
Consulting or Advisory Role - Amgen; Apogepha; Astellas Pharma; Bayer/Vital; Janssen-Cilag; Merck; MSD; Novartis; Orion; Solution Akademie GmbH
Travel, Accommodations, Expenses - Amgen; Apogepha; Astellas Pharma; Bayer; Janssen; MSD
 
Cyrus Sayehli
Honoraria - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Celgene
 
Alejandro Navarro
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Pfizer; Roche
Expert Testimony - Oryzon Genomics
Travel, Accommodations, Expenses - Boehringer Ingelheim; Pfizer
 
Bhumsuk Keam
Consulting or Advisory Role - AstraZeneca; Genexine; MSD Oncology
Research Funding - AstraZeneca; MSD Oncology; Ono Pharmaceutical
 
Ana-Maria Piciu
Employment - Bayer
 
Sebastian Bender
Employment - Bayer
 
Hendrik Nogai
Employment - Bayer
 
Peter Ellinghaus
Employment - Bayer
 
Martin H. Schuler
Honoraria - Abbvie; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; MSD; Novartis; Pierre Fabre
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Novartis; Roche
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Highly sensitive method for mutation detection by PCR (Inst)